{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:31:56Z","timestamp":1793975516586,"version":"4.8.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1097\/ppo.0000000000000100","type":"journal-article","created":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T18:13:02Z","timestamp":1427479982000},"page":"117-122","source":"Crossref","is-referenced-by-count":81,"title":["Cancer Cachexia, Recent Advances, and Future Directions"],"prefix":"10.1097","volume":"21","author":[{"given":"Marie-France","family":"Penet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaver M.","family":"Bhujwalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210203","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus.","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"R2-11-20210203","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00423-004-0486-7","article-title":"Cancer cachexia.","volume":"389","author":"Tisdale","year":"2004","journal-title":"Langenbecks Arch Surg"},{"key":"R3-11-20210203","first-page":"5022","article-title":"Inhibition of weight loss by omega-3 fatty acids in an experimental cachexia model.","volume":"50","author":"Tisdale","year":"1990","journal-title":"Cancer Res"},{"key":"R4-11-20210203","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/canjclin.57.4.225","article-title":"The lethal phenotype of cancer: the molecular basis of death due to malignancy.","volume":"57","author":"Loberg","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"R5-11-20210203","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia.","volume":"89","author":"Tisdale","year":"2009","journal-title":"Physiol Rev"},{"key":"R6-11-20210203","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia.","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"R7-11-20210203","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways.","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab"},{"key":"R8-11-20210203","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","article-title":"A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly andor poor performance non-small cell lung cancer patients (N01C9).","volume":"68","author":"Jatoi","year":"2010","journal-title":"Lung Cancer"},{"key":"R9-11-20210203","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","article-title":"A switch from white to brown fat increases energy expenditure in cancer-associated cachexia.","volume":"20","author":"Petruzzelli","year":"2014","journal-title":"Cell Metab"},{"key":"R10-11-20210203","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-013-2611-8","article-title":"Molecular imaging of brown adipose tissue in health and disease.","volume":"41","author":"Bauwens","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-11-20210203","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature13528","article-title":"Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia.","volume":"513","author":"Kir","year":"2014","journal-title":"Nature"},{"key":"R12-11-20210203","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.20122344","article-title":"Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia.","volume":"210","author":"Roberts","year":"2013","journal-title":"J Exp Med"},{"key":"R13-11-20210203","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/jcp.24580","article-title":"Pancreatic cancer-induced cachexia is Jak2-dependent in mice.","volume":"229","author":"Gilabert","year":"2014","journal-title":"J Cell Physiol"},{"key":"R14-11-20210203","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MCO.0000000000000032","article-title":"Omega-3 fatty acids and protein metabolism: enhancement of anabolic interventions for sarcopenia.","volume":"17","author":"Di Girolamo","year":"2014","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R15-11-20210203","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/MCO.0000000000000075","article-title":"Ghrelin: from discovery to cancer cachexia therapy.","volume":"17","author":"Molfino","year":"2014","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R16-11-20210203","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1210\/jc.2003-031768","article-title":"Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial.","volume":"89","author":"Neary","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-11-20210203","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","article-title":"Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study.","volume":"21","author":"Garcia","year":"2013","journal-title":"Support Care Cancer"},{"key":"R18-11-20210203","first-page":"611","article-title":"Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice.","volume":"123","author":"Porporato","year":"2013","journal-title":"J Clin Invest"},{"key":"R19-11-20210203","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1517\/14712598.2013.748031","article-title":"The hunger hormone ghrelin in cachexia.","volume":"13","author":"Molfino","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"R20-11-20210203","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13539-014-0159-5","article-title":"Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile.","volume":"5","author":"Pietra","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R21-11-20210203","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"R22-11-20210203","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11739-010-0426-1","article-title":"The parallel pathway: a novel nutritional and metabolic approach to cancer patients.","volume":"6","author":"Muscaritoli","year":"2011","journal-title":"Intern Emerg Med"},{"key":"R23-11-20210203","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1158\/1078-0432.CCR-09-1525","article-title":"Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer.","volume":"15","author":"Tan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R24-11-20210203","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","article-title":"Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.","volume":"15","author":"Prado","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R25-11-20210203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1634\/theoncologist.2010-0019","article-title":"More is better: a multimodality approach to cancer cachexia.","volume":"15","author":"del Fabbro","year":"2010","journal-title":"Oncologist"},{"key":"R26-11-20210203","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"R27-11-20210203","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3945\/ajcn.2008.27273","article-title":"A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands.","volume":"89","author":"Lieffers","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"R28-11-20210203","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2009.24.9730","article-title":"Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.","volume":"28","author":"Antoun","year":"2010","journal-title":"J Clin Oncol"},{"key":"R29-11-20210203","first-page":"307","article-title":"Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer J Cachexia Sarcopenia Muscle.","volume":"5","author":"Fogelman","year":"2014","journal-title":""},{"key":"R30-11-20210203","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clnu.2010.07.012","article-title":"Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopeniacancer cachexia.","volume":"30","author":"Gray","year":"2011","journal-title":"Clin Nutr"},{"key":"R31-11-20210203","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/02841860802130001","article-title":"Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia.","volume":"48","author":"Weber","year":"2009","journal-title":"Acta Oncol"},{"key":"R32-11-20210203","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00520-013-2081-3","article-title":"Phase III trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy.","volume":"22","author":"Greig","year":"2014","journal-title":"Support Care Cancer"},{"key":"R33-11-20210203","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1158\/0008-5472.CAN-11-1095","article-title":"Metabolic signatures imaged in cancer-induced cachexia.","volume":"71","author":"Penet","year":"2011","journal-title":"Cancer Res"},{"key":"R34-11-20210203","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF00402783","article-title":"Brown adipose tissue in cancer patients: possible cause of cancer-induced cachexia.","volume":"111","author":"Shellock","year":"1986","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:21:30Z","timestamp":1620969690000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201503000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000100","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}